Bispecific Nanosystems Enable Multieffector Immune Cell Retargeting for Hematologic Malignancy Therapy.

ABSTRACT: B-cell lymphomas are hematologic malignancies characterized by poor prognoses. Immunotherapy has revolutionized B-cell lymphoma treatment by harnessing immune effector cells, but current therapeutic strategies face limitations: suboptimal pharmacokinetics of bispecific antibodies and high complexity and cost of chimeric antigen receptor T-cell therapies. To address these challenges, a bispecific nanosystem (biHSNPs) is developed that exploits the multi-functional customizability of silica nanoplatform to conjugate antibodies targeting cytotoxic T cells or natural killer cells, alongside effector antibodies specific to B-cells. Four biHSNPs with different effector and target antibodies are synthesized. This bispecific nanosystem enables simultaneous binding to immune effector cells and B-ce

SUBMITTER: Shen Y 

PROVIDER: S-EPMC12533383 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature